Clinical trial · Interventional
Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation
The Effects of Dose and Formulation of Oral Contraceptives (OCs) on Breast-Cell Proliferation: Can the Chemopreventive Effects of OCs on Endometrial and Ovarian Cancer be Extended to Breast Cancer?
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to gain a better understanding of the changes that may occur in the breast when a woman uses an oral contraceptive (birth control pill). Some research indicates that women who use birth control pills with lower amounts of estrogen (a hormone in the birth control pill) may have lower breast cell growth than women who use birth control pills with a higher amount of estrogen; this research will examine that in detail.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Contraceptive | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oral Contraceptive: Microgestin Fe® 1/20 | Drug | — | UNRESOLVED |
| Oral Contraceptive: Ortho-Novum® 1/35 | Drug | — | UNRESOLVED |
| Oral Contraceptive: Ovcon® 35 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Ortho-Novum® 1/35
- description
- Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
- interventionNames
- Drug: Oral Contraceptive: Ortho-Novum® 1/35
- type
- ACTIVE_COMPARATOR
- label
- Ovcon® 35
- description
- Ovcon® 35 is an oral contraceptive that contains less progestin.
- interventionNames
- Drug: Oral Contraceptive: Ovcon® 35
- type
- ACTIVE_COMPARATOR
- label
- Microgestin Fe® 1/20
- description
- is an oral contraceptive that contains less estrogen.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18-35 2. BMI \<30 kg/m2 3. Premenopausal with regular cycles or currently taking an OC 4. Not currently or recently pregnant or nursing (within previous 6 months) 5. Non-smoker 6. No use of antibiotics within the prior 4 weeks 7. Competent to provide written informed consent (as judged by study team) 8. Willing to adhere to the OC regimen 9. Willingness to refrain from the use of aspirin or NSAIDS 10 days pior to the biopsy appointment and one week following the biopsy procedure 10. Willing and able to refrain from use of fish oils 10 days prior to the biopsy appointment and one week following the biopsy procedure Exclusion Criteria: 1. Diabetes 2. Abnormal breast examination 3. Abnormal PT/INR and/or CBC with platelets test results (as determined by one of the study physicians) 4. History or current therapeutic or prophylactic use of anticoagulants 5. Known bleeding disorder or history of unexplained bleeding or bruising 6. History of breast cancer or previous diagnostic breast biopsy 7. Known allergy to local anesthetic
References
Publications (0)
Data not yet available